Sirolimus given into the brain to prevent hydrocephalus after brain bleeding
Tests sirolimus in adults with hydrocephalus after bleeding in the brain.
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 15 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Treatments tested
- Sirolimus (Rapamune®)
- Record updated
- 25 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with severe bleeding in the brain from a burst aneurysm, with blood in the brain's fluid spaces. They must need a temporary brain drain (EVD) as part of usual care.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Aneurysmal subarachnoid hemorrhage (bleeding around the brain from a burst aneurysm), Hunt Hess grade IV to V (severe). Scans must show bleeding into the brain's fluid spaces (intraventricular hemorrhage).
- Earlier treatment
- An external ventricular drain (EVD) must be placed as part of standard care. People should join soon after, ideally within 24 hours of EVD placement.
Main reasons for not taking part
- Already depending on a ventriculoperitoneal shunt (a permanent brain fluid drain)
- Severely weakened immune system
- Uncontrolled body-wide infection not related to the bleeding
- Pregnancy
- Life-support expected to be stopped within 24 hours
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age ≥18 years
- Diagnosis of aneurysmal subarachnoid hemorrhage (aSAH)
- Hunt Hess grade IV to V
- Radiographic evidence of intraventricular hemorrhage (IVH)
- Clinically indicated EVD placement as part of standard neurocritical care
- Ability to enroll during the acute post-hemorrhagic inflammatory period, ideally within 24 hours of EVD placement
Who cannot take part
- Anticipated withdrawal of life-sustaining therapy within 24 hours
- Inability to safely receive investigational ventricular therapy
- Uncontrolled systemic infection unrelated to hemorrhage
- Pre-existing ventriculoperitoneal shunt dependence
- Severe baseline immunosuppression
- Pregnancy
Where in United States
- Massachusetts General Hospital Lunder 4 OR for adult surgeriesBoston, United StatesContact: Carla Fortes, BANot yet recruiting
About the trial
What the trial wants to find out
Hydrocephalus is a serious condition in which fluid builds up inside the brain, often requiring lifelong surgical placement of a shunt to drain excess cerebrospinal fluid (CSF). One of the most common causes of hydrocephalus is bleeding into the brain's fluid spaces after aneurysm rupture, prematurity, or infection. Currently, no medication exists to prevent hydrocephalus from developing after these injuries. The investigators' recent research suggests that hydrocephalus may result not only from blocked fluid pathways but also from harmful inflammation within the brain's ventricular system. The investigators discovered that inflammation activates the choroid plexus, the tissue that produces CSF, causing excessive CSF production and inflammatory injury to the ventricular lining and surrounding brain tissue. The investigators also identified inflammatory biomarkers and extracellular vesicles in human CSF that may enable real-time monitoring of these disease processes.
Read full original descriptionShow less
In this project, the investigators will perform a first-in-human pilot study testing whether targeted "intraventricular mTOR inhibition" can reduce ventricular inflammation and prevent hydrocephalus after severe brain hemorrhage. The medication will be delivered via temporary ventricular drains already in place as part of routine clinical care. The investigators will study safety, inflammation, CSF production, brain imaging changes, and whether patients ultimately require permanent shunts. Although this initial study focuses on adults with hemorrhage-related hydrocephalus, our long-term goal is to develop non-surgical therapies that could help children with hydrocephalus caused by prematurity or infection, especially in regions where access to neurosurgical care and shunt surgery is limited.
The group in the trial
- Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain HemorrhageTreatment being tested
The investigators will conduct a prospective, single-center, phase Ib/IIa, biomarker-rich translational pilot study evaluating intraventricular mTOR inhibition in adults with severe aneurysmal subarachnoid hemorrhage (aSAH) who require external ventricular drain (EVD) placement as part of routine neurocritical care management. The central objective of the study is to determine whether early modulation of ventricular immune-secretory signaling is feasible, biologically active, and capable of altering inflammatory CSF physiology and ventricular remodeling following hemorrhage.
Treatment: Sirolimus (Rapamune®)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- VENTURE-PHH: Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage
- Plain-language title
- Sirolimus given into the brain to prevent hydrocephalus after brain bleedingGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 25 June 2026